Development of antiviral therapy for severe acute respiratory syndrome

被引:54
作者
Cinatl, J [1 ]
Michaelis, M [1 ]
Hoever, G [1 ]
Preiser, W [1 ]
Doerr, HW [1 ]
机构
[1] Univ Frankfurt Klinikum, Inst Med Virol, D-60596 Frankfurt, Germany
关键词
anti-viral therapy; SARS-CoV; ribavirin;
D O I
10.1016/j.antiviral.2005.03.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:81 / 97
页数:17
相关论文
共 197 条
[1]   Suppression of Herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2) [J].
Adler, H ;
Beland, JL ;
DelPan, NC ;
Kobzik, L ;
Brewer, JP ;
Martin, TR ;
Rimm, IJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (09) :1533-1540
[2]   Pathogenesis of influenza virus-induced pneumonia: Involvement of both nitric oxide and oxygen radicals [J].
Akaike, T ;
Noguchi, Y ;
Ijiri, S ;
Setoguchi, K ;
Suga, M ;
Zheng, YM ;
Dietzschold, B ;
Maeda, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (06) :2448-2453
[3]   Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus [J].
Åkerström, S ;
Mousavi-Jazi, M ;
Klingström, J ;
Leijon, M ;
Lundkvist, Å ;
Mirazimi, A .
JOURNAL OF VIROLOGY, 2005, 79 (03) :1966-1969
[4]  
Ali M B, 2003, Hong Kong Med J, V9, P391
[5]   Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs [J].
Anand, K ;
Ziebuhr, J ;
Wadhwani, P ;
Mesters, JR ;
Hilgenfeld, R .
SCIENCE, 2003, 300 (5626) :1763-1767
[6]   An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses [J].
André, P ;
Groettrup, M ;
Klenerman, P ;
de Giuli, R ;
Booth, BL ;
Cerundolo, V ;
Bonneville, M ;
Jotereau, F ;
Zinkernagel, RM ;
Lotteau, V .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) :13120-13124
[7]  
Avendano M, 2003, CAN MED ASSOC J, V168, P1649
[8]   Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro [J].
Bacha, U ;
Barrila, J ;
Velazquez-Campoy, A ;
Leavitt, SA ;
Freire, E .
BIOCHEMISTRY, 2004, 43 (17) :4906-4912
[9]   Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine [J].
Baltina, LA .
CURRENT MEDICINAL CHEMISTRY, 2003, 10 (02) :155-171
[10]  
Balzarini J, 2004, ANTIVIR RES, V62, pA59